1910 Genetics

Today we announced a groundbreaking five-year commercial agreement and go-to-market collaboration with Microsoft to build the infrastructure layer for drug discovery using #AI and high performance computing. ? This first of its kind, fully integrated, drug discovery and development platform will combine 1910’s massive, computational and wet lab biological data, robotics-driven laboratory automation and multimodal AI models for drug discovery with Microsoft’s next-generation high-performance computing platform, Azure Quantum Elements. ? The platform will be offered to potential pharmaceutical, biotechnology, government, academic, and research institutions via three partnership models: Co-discovery, Co-engineering, and Platform-as-a-Service. ? Together we will accelerate scientific discovery and empower pharmaceutical R&D teams worldwide to generate therapeutics faster and more cost-effectively. Press Release: https://lnkd.in/eHwmiNXH Customer Sign-up Form: https://lnkd.in/ek9dbk3T?

Congratulations to Drs. David Baker, Demis Hassabis, and John Jumper for winning The Nobel Prize in Chemistry! This marks the second Nobel Prize for AI in 2 days! At 1910,?our work in large molecule AI drug discovery began with AI-driven protein structure prediction. In 2018, tools like Rosetta were able to predict the N-terminal to C-terminal backbone structure of proteins but sometimes, not with high enough resolution to predict the conformations of the unique side chain attached to each amino acid. Protein structures are defined by hydropathic interaction (HINT) networks on multiple scales.?These networks are hydrophobic as well as electrostatic/hydrogen?bonding, and?include favorable and unfavorable elements.?Three-dimensional (3D) hydropathic interaction maps calculated by HINT encode these networks on a residue-by-residue basis. Importantly, these HINT maps can be clustered – reducing thousands of residue environments into ~18 maps on average – each with a unique side chain conformation and set of interactions. Through a?2019?collaboration with Dr. Glen Kellogg of Virginia Commonwealth University, 1910 developed a methodology for processing all 20 amino acids, thereby generating 12,000,000 HINT maps, yielding > 4,000 unique backbone maps and?>10,000 unique side chain maps for about 800 total chess squares.?This dataset?was an unprecedented collection of information-rich 3D maps that encoded the hydropathic interaction environments favored by each amino acid residue.?We then?built AI and ML models to?leverage?our proprietary HINT map dataset for a variety of applications?including?side chain prediction, homology modeling, 3D protein structure prediction, and?de novo?protein design. With AlphaFold2, predicting both the structure of protein backbones and amino acid side chain?conformations?became possible, thereby solving a holy grail problem that was intractable for decades. While our work in large molecule AI drug discovery had roots in the prediction of protein side chain conformations, it has since expanded to include?de novo?design and optimization of large molecule therapeutics such as traditional monoclonal antibodies, Fabs, VHHs, antibody-drug conjugates, etc. Congratulations to Drs. Baker, Hassabis and Jumper for their well-deserved Nobel Prize, and for showing yet again, the tremendous promise of AI to revolutionize drug discovery!

Congratulations to Drs. Hopfield and Hinton for receiving The Nobel Prize in Physics for their groundbreaking work in machine learning and artificial neural networks. Their pioneering discoveries, including Hopfield Networks and the Boltzmann machine, have shaped the foundation of modern AI. We are proud to build upon these revolutionary advances, harnessing the power of AI to drive innovation in drug discovery and development. Their work continues to inspire our mission to unlock new possibilities in biopharma and improve patient outcomes through the transformative potential of AI.

Tomorrow, our Founder & CEO, Jen Nwankwo, Ph.D., will dive into the transformative potential of AI in biopharma during a fireside chat with Helen H. Liang, PhD of FoundersX Ventures at SF TECH WEEK by a16z. Don’t miss this exciting conversation on how we are leveraging cutting edge advancements in AI, such as agents and their underlying agentic systems to shape the future of drug discovery and development. Visit the event website to learn more or RSVP for the in-person event: https://bit.ly/4gUQDgA

We're thrilled to announce that the AI Drug Discovery Panel is now available for on-demand viewing! ? Don't miss our Founder & CEO, Jen Nwankwo, Ph.D., as she shares her insights on the buzz around AI in drug discovery alongside other thought leaders in the field.

TODAY! Our Founder & CEO, Jen Nwankwo, Ph.D. will participate in this panel with AI thought leaders, and discuss how 1910 Genetics is overcoming the data, compute, and model barriers that are limiting the impact of AI in Drug Discovery!

Congratulations to Liping Wu, PhD, Lakshmi Gayitri Chivukula, Francis Acquah, and Sidharth S. on their promotions. The 1910 Genetics team appreciates you for bringing our “Grit, Mission Driven, and Sense of Ownership” values to life!? ? To learn more about our values and open roles, please visit our careers page: https://lnkd.in/eMAeMkBs? ?? #AIInnovation #Biology #1910Genetics

Last Saturday, our Founder & CEO, Jen Nwankwo, Ph.D. was the Opening Keynote Speaker at the Biomedical Science Careers Program (BSCP) Alumni Conference at Harvard Medical School. ? In her Keynote speech, "A Conversation on Courageous & Inclusive Leadership," she reflected on the courage it took to found 1910 Genetics, and how courage requires privilege, which is all too often lacking for people of color. ? Our CEO's Keynote Speech set the tone for the rest of the day, including the panel she moderated featuring incredible leaders - Dennise A. De Jesús-Díaz, Emerson Foster, and Mark M Melendez MD, MBA. Jen's authenticity about the challenges and triumphs of leadership resonated deeply with the audience. The day was filled with inspiring conversations, including a fireside chat with Dr. Joan Reede and Dr. Uché Blackstock, MD, highlighting their remarkable journeys and contributions to medicine.? ?? We're excited about the future and the potential collaborations inspired by this conference. Thank you to everyone who made this event memorable.? ?? #BSCP2024 #InclusiveLeadership #1910Genetics

Thank you Drug Discovery & Development for covering our Microsoft Azure Quantum collaboration which will provide pharma companies an integrated drug discovery and development platform combining AI, advanced computing, and laboratory automation to accelerate?pharmaceutical R&D.? ? With fewer iterations needed to reach the final molecule for clinical trials, we're on track to significantly shorten the drug discovery process and deliver higher-quality drug candidates to the market faster than ever before. ? We're excited to offer our platform via Co-Discovery, Co-Engineering, and Platform-as-a-Service partnership models to customers. Learn more here: https://lnkd.in/ek9dbk3T? ? Read the article here: https://lnkd.in/dAPz_rXZ? ? Thank you Brian K. Buntz!? ? #Biotech #AI #DrugDiscovery #Microsoft #AzureQuantum #1910Genetics?

Boston Business Journal covered our partnership with Microsoft which supports our mission to accelerate pharmaceutical R&D more affordably for pharma, biotechnology, government, academic, and research institutions worldwide. Our CEO and founder, Jen Nwankwo, Ph.D., shared, “Microsoft is one of the best companies in the world at building enterprise and global-scale software. [1910 Genetics is] really good at doing drug discovery and when the both of us come together, it’s almost like drug discovery on steroids.”? ? We're excited to offer our platform via Co-Discovery, Co-Engineering, and Platform-as-a-Service partnership models to customers. Learn more here: https://lnkd.in/ek9dbk3T Read the Boston Business Journal article here: https://lnkd.in/eRdri9YH? ? Thank you Hannah Green for this feature!? ? #1910Genetics #Microsoft #DrugDiscovery #AI?